Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies

References

• American Cancer Society. Global cancer facts & figures 3rd edition. Atlanta: American Cancer Society; 2015; 2015.
   Google Scholar
• WHO. Cancer Fact sheet N°297. 2015 Feb.
   Google Scholar
• Matveeva OV, Guo ZS, Senin VM, Senina AV, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics. 2015;2. doi:10.1038/mto.2015.17.
   Web of Science ®Google Scholar
• Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12(2):141–161. doi:10.1038/sj.cgt.7700771. PMID: 15472714.
   PubMed Web of Science ®Google Scholar
• Haddad D, Fong Y. Molecular imaging of oncolytic viral therapy. Mol Ther Oncolytics. 2015;1:14007. doi:10.1038/mto.2014.7. PMID: 27119098.
   PubMedGoogle Scholar
• Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18(2):251–263. doi:10.1038/mt.2009.283. PMID: 20029399.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18(7):2080–2089. doi:10.1158/1078-0432.CCR-11-2181. PMID:22316603.
   PubMed Web of Science ®Google Scholar
• Pack GT. Note on the experimental use of rabies vaccine for melanomatosis. AMA Arch Derm Syphilol. 1950;62(5):694–695. doi:10.1001/archderm.1950.01530180083015. PMID: 14770525.
   PubMedGoogle Scholar
• Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I, Russell SJ, Galanis E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther. 2008;15(14):1024–1034. doi:10.1038/gt.2008.30. PMID: 18356818.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol. 2009;330:213–241. PMID:19203112.
   PubMed Web of Science ®Google Scholar
• Yanagi Y, Takeda M, Ohno S, Hashiguchi T. Measles virus receptors. Curr Top Microbiol Immunol. 2009;329:13–30. PMID: 19198560.
   PubMed Web of Science ®Google Scholar
• Zhang LF, Tan DQ, Jeyasekharan AD, Hsieh WS, Ho AS, Ichiyama K, Ye M, Pang B, Ohba K, Liu X, et al. Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. Cancer Lett. 2014;354(2):272–280. doi:10.1016/j.canlet.2014.08.034. PMID: 25193462.
   PubMed Web of Science ®Google Scholar
• Fujiyuki T, Yoneda M, Amagai Y, Obayashi K, Ikeda F, Shoji K, Murakami Y, Sato H, Kai C. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells. Oncotarget 2015;6(28):24895–24903. doi:10.18632/oncotarget.4366. PMID: 26317644.
   PubMedGoogle Scholar
• Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C. Oncolytic activity of a recombinant measles virus, blind to signaling lymphocyte activation molecule, against colorectal cancer cells. Sci Rep 2016;6:24572. doi:10.1038/srep24572. PMID: 27090874.
   PubMed Web of Science ®Google Scholar
• Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines. 2010;9(11):1275–1302. doi:10.1586/erv.10.124. PMID:21087107.
   PubMed Web of Science ®Google Scholar
• Harfast B, Andersson T, Alsheikhly A, Perlmann P. Effect of Fc-receptor modulation on mumps-virus-dependent lymphocyte-mediated cytotoxicity in vitro. Scand J Immunol 1980;11(3):357–362. doi:10.1111/j.1365-3083.1980.tb00246.x. PMID: 9537065.
   PubMed Web of Science ®Google Scholar
• Ammayappan A, Russell S, Federspiel M. Recombinant mumps virus as a cancer therapeutic agent. Mol Ther-Oncolytics. 2016;3. doi:10.1038/mto.2016.19. PMID: 27556105.
   PubMed Web of Science ®Google Scholar
• Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A, Ogihara K, Naya Y, Ikeda F, Matsuda H, et al. Development of new therapy for canine mammary cancer with recombinant measles virus. Mol Ther Oncolytics. 2016;3:15022. doi:10.1038/mto.2015.22. PMID:27119113.
   PubMed Web of Science ®Google Scholar
• Krysko O, Love AT, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:e631. doi:10.1038/cddis.2013.156. PMID:23681226.
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Brown M, Wiedmann RT, Hartzel J, Musey L. Safety and immunogenicity of M-M-RII (Combination measles-mumps-rubella vaccine) in clinical trials of healthy children conducted between 1988 and 2009. Pediatr Infect Dis J. 2016;35(9):1011–1020. doi:10.1097/INF.0000000000001241. PMID:27254037.
   PubMed Web of Science ®Google Scholar
• Matveeva OV, Guo ZS, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics. 2015;2. doi:10.1038/mto.2015.11.
   Web of Science ®Google Scholar
• Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006;34(6):713–720. doi:10.1016/j.exphem.2006.03.002. PMID: 16728275.
   PubMed Web of Science ®Google Scholar
• Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, Subjeck JR. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today 2006;11(11-12):534–540. doi:10.1016/j.drudis.2006.04.016. PMID:16713905.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Patel B, Dey A, Ghorani E, Rai L, Elham M, Castleton AZ, Fielding AK. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function. J Immunol. 2012;188(3):1002–1010. doi:10.4049/jimmunol.1102262. PMID:22180616.
   PubMed Web of Science ®Google Scholar
• Ulane CM, Rodriguez JJ, Parisien JP, Horvath CM. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 2003;77(11):6385–6393. doi:10.1128/JVI.77.11.6385-6393.2003. PMID:12743296.
   PubMed Web of Science ®Google Scholar
• Kubota T, Yokosawa N, Yokota S, Fujii N, Tashiro M, Kato A. Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol. 2005;79(7):4451–4459. doi:10.1128/JVI.79.7.4451-4459.2005. PMID:15767445.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Parisien JP, Horvath CM. STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J Virol. 2008;82(17):8330–8338. doi:10.1128/JVI.00831-08. PMID: 18579593.
   PubMed Web of Science ®Google Scholar
• Vandenberk L, Belmans J, Van WM, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol 2015;6:663. PMID:26834740.
   PubMed Web of Science ®Google Scholar
• Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing. Eur J Immunol.2016;46(4):919–928. doi:10.1002/eji.201545915. PMID:26763072.
   PubMed Web of Science ®Google Scholar
• Servet-Delprat C, Vidalain PO, Azocar O, Le DF, Fischer A, Rabourdin-Combe C. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J Virol. 2000;74(9):4387–4393. doi:10.1128/JVI.74.9.4387-4393.2000. PMID:10756053.
   PubMed Web of Science ®Google Scholar